StockDuty ← Dashboard Nov 16, 2026 11:44 PM ET
SignalTech/AI

Early progress on accelerating drug development with Claude

Claude shows early progress accelerating drug development, signaling AI use in pharma R&D.

What happened: Anthropic's life sciences team said it has partnered with six organizations on drug development work using Claude, including BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group, and has begun its own drug discovery efforts. Key numbers: Six partner organizations. Why it matters: Anthropic says the work has already led it to prioritize specific model improvements, and that the programs can serve as case studies for the wider life sciences community. It plans to scale the work up substantially.
Anthropic's life sciences team said it has partnered with six organizations on drug development work using Claude, including BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group, and has begun its own drug discovery efforts.
Anthropic says the work has already led it to prioritize specific model improvements, and that the programs can serve as case studies for the wider life sciences community. It plans to scale the work up substantially.
Sources